Covid-19 man­u­fac­tur­ing roundup: Biden pumps $500M in­to do­mes­tic test­ing pro­duc­tion; Val­ne­va mulls pro­duc­tion deal

The US De­part­ment of Health and Hu­man Ser­vices has in­vest­ed an ad­di­tion­al $562 mil­lion in US com­pa­nies to boost the do­mes­tic man­u­fac­tur­ing of Covid-19 tests and sup­plies, it an­nounced last week.

A dozen com­pa­nies were re­cip­i­ents of the fund­ing, which in­clud­ed mon­ey to sup­port the man­u­fac­tur­ing of pipette tips, pro­tec­tive pack­ag­ing, swabs and reagents used to de­tect the virus in sam­ples.

Among the re­cip­i­ents were Ora­Sure Tech­nolo­gies, which re­ceived $109 mil­lion to retro­fit a man­u­fac­tur­ing fa­cil­i­ty and build a new one to up do­mes­tic man­u­fac­tur­ing for rapid anti­gen self-tests; Cepheid, which land­ed $63.8 mil­lion to pro­duce plas­tic over mold; and Nalge Nunc In­ter­na­tion­al, a sub­sidiary of Ther­mo Fish­er Sci­en­tif­ic, which took home $192.5 mil­lion to ramp pipette tip man­u­fac­tur­ing for sam­ple col­lec­tion and test pro­cess­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.